NCT05065255 (Eva) is a clinical trial of SpeediCath® catheters in Urinary Retention, sponsored by Laboratoires Coloplast S.A.S.

Who is sponsoring NCT05065255?

NCT05065255 is sponsored by Laboratoires Coloplast S.A.S.

What drugs are being tested in NCT05065255?

Interventions in NCT05065255: SpeediCath® catheters.

What condition does NCT05065255 study?

NCT05065255 studies Urinary Retention.

Is NCT05065255 still recruiting?

NCT05065255 is currently status unknown. Last updated 11 March 2022.

Last reviewed 2022-03-11 · How we verify

NCT05065255: Eva

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of the Criteria for Choosing Speedicath Catheters During the Initiation of Self-catheterization

Status unknown Last updated 11 March 2022

What this trial tests

trial testing SpeediCath® catheters in Urinary Retention in 250 participants. Status unknown.

Timeline

30 September 2021

Primary endpoint
30 January 2023

30 January 2023

Quick facts

Lead sponsor	Laboratoires Coloplast S.A.S
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	250
Start date	30 September 2021
Primary completion	30 January 2023
Estimated completion	30 January 2023
Sites	38 locations across France

Drugs / interventions tested

SpeediCath® catheters

Conditions studied

Urinary Retention — all drugs for Urinary Retention →

Sponsor

Laboratoires Coloplast S.A.S

Who can join

18 and older, any sex, with Urinary Retention. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To date, there is no objective data to help in the choice of the type of catheter to offer to the patient according to his or her needs. Although it is now known that the quality of life of patients practicing intermittent self catheterisation is dependent on multiple factors, there is little data on the factors that facilitate or hinder adherence to intermittent self catheterisation during the first six months after initiation of intermittent self catheterisation. The prospective multicenter exploratory observational study that the sponsor wishes to conduct aims to determine what criteria preside over patient choice of SpeedyCath (SC) leads. This information would allow us to set up a personalized advice with each patient in the future, with the aim of proposing the SC catheter best adapted to his needs. The study population will consist of adults with neurogenic or non-neurogenic urinary disorders that warrant the use of intermittent self catheterisation, with intermittent self catheterisation education occurring at the time of inclusion. Patients should be autonomous in the practice of intermittent self catheterisation, and the minimum expected duration of follow-up should be greater than or equal to 6 months. Only patients who choose to use SpeediCath leads will be included in the study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Urinary Retention

Currently open trials in the same condition.

NCT07372547 — Effect of Voiding Position (Standing in the Shower vs. Sitting) on Post-Void Residual Urine Volume (PVR) After Removal o · NA · recruiting
NCT07355803 — Define Final Selection Choice Criteria for a Coloplast Catheter Ensuring Highest Patient Satisfaction Via Surveys (EVA). · NA · recruiting
NCT06978205 — Effect of Urethral Balloon Dilatation on Urinary Retention After Spinal Cord Injury · NA · recruiting
NCT06163469 — Effect of Chlorhexidine Gluconate Bladder Instillations in Patients With Chronic Suprapubic Catheters on Unplanned Healt · NA · recruiting
NCT06179654 — Preoperative Pelvic Floor Physical Therapy to Minimize Stress Urinary Incontinence After Holmium Laser Enucleation of th · NA · recruiting

Other Laboratoires Coloplast S.A.S trials

Trials by the same sponsor.

NCT04635215 — Observational Study of the Quality of Life of New Ostomates Using SenSura Mio Appliances With BodyFit Technology · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05065255 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Laboratoires Coloplast S.A.S
Last refreshed: 11 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05065255.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing